Project description:The non-small cell lung carcinoma (NSCLC) PC9 cell line is an established preclinical model for tyrosine kinase inhibitors. To better understand gene expression changes in cells that survived the inhibitor treatment, we treated the EGFR-mutant PC9 cells with erlotinib, isolated RNA, and performed RNA-seq analysis. We were able to identify genes that are differentially expressed in erlotinib-treated cells compared to untreated. The results of this study will be integrated with single cell RNA-seq to address the utility of bulk RNA versus single cell RNA strategies in identifying biomarkers of drug resistance.
Project description:Single-probe single cell mass spectrometry (SCMS) analysis contains 3 sets of experiments:
1. SCMS analysis of 4 groups of cells: infected, bystanders, stained and control cells
2. SCMS analysis of 3 groups of cells (2 replicates): infected, correctly classified bystander, misclassified bystander cells.
3. SCMS-MS of 5 glycerophosphocholines at m/z 768.583, 780.5460, 782.5630, 808.5770 and 810.5940 that were acquired from individual HeLa cells.
Project description:We edited an intronic IL2RA enhancer or exon in primary human naïve T cells. Electroporated cells were activated and sorted on IL2RA expression over three days. Amplicon sequencing was used to assess the effects on sequence edits on IL2RA expression.
Project description:We used a new technology, named Detect-seq, to perform genome sequencing on transfected HEK293T cells to see DdCBEs' off-target mutations. Besides, targeted-amplicon sequencing and ATAC-seq data were applied to validate the results of Detect-seq.
Project description:We used a new technology, named Detect-seq, to perform genome sequencing on transfected HEK293T cells to see DdCBEs' off-target mutations. Besides, targeted-amplicon sequencing and ATAC-seq data were applied to validate the results of Detect-seq.
Project description:Inevitable gefitinib resistance and relapse of the disease was the biggest hurdle to NSCLC treatment. Importantly, the role of hypoxia in solid tumor tissues in vivo in gefitinib acquired resistance and its relationship to lung cancer stem cells (LCSCs) has not been fully elucidated. Here, the PC9 cells were treated with short term gefitinib or/and hypoxia, also, PC9 gefitnib resistant (PC9-GR) cell line was established and ALDH positive PC9 cells were sorted by FACs. Transcriptome analysis among those PC9 cell groups revealed the important role of hypoxia in gefitinib acquired resistance and signaling transduction change, which may critical for NSCLC disease progression and recurrence.